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Analysis of longitudinal nef sequence variation through-
out HIV-2 infection
M. Remedios1,∗, E. Paixao1, H. Feliciano2, A. Silva-Graca2,
E. Pádua1
1 National Institute of Health, Lisbon, Portugal
2 Hospital Militar de Belém, Lisbon, Portugal
Background: Human Immunodeﬁciency Virus type 1 (HIV-
1) and type 2 (HIV-2) may case a severe immunodeﬁciency in
humans (AIDS). However HIV-2 is more frequently associated
with lower levels of transmission and disease progression,
compared with HIV-1 infections. The role of nef gene in vivo
during the development of AIDS has been clearly demon-
strated in simian immunodeﬁciency virus infected Rhesus
macaques model, but the determinants which play a role
in the pathogenesis of HIV are relatively poorly understood.
However, even less is known about the role of nef in HIV-2
infections.
Methods: In this study, it was analyzed the variation
of 48 nef gene sequences, obtained from samples taken
between 1994 and 2009, corresponding to 17 HIV-2-infected
individuals with different clinical stages of infection. The
sequences obtained by Nested PCR were classiﬁed by phylo-
genetic analysis and the functional protein motifs, described
as important in CD4 and MHC-I downregulation and in viral
infectivity were also analyzed.
Results: In all individuals were identiﬁed nef sequences
from group A of HIV-2, which encoded possible functional
and complete protein. There was a greater conserva-
tion of residues in the Nef sequences of individuals in
the symptomatic stage (63%), comparatively to individuals
in the asymptomatic stage (19%). While some functional
motifs (MGxxxS1, DDDD93, RR137 and DD205) and also
residues (G128, I141 and L142) remained conserved, others
(YSRF39, LRAR21, PxxP101, EE185) revealed changes dur-
ing the follow-up period. The PxxP motif exhibited wide
inter-individual variation in vivo from an HIV-1-like tetra-
proline motif (PxxP)3 to disruption of the minimal core
PxxPLR motif. The disruption was observed in 11 sequences
exclusively from asymptomatic individuals (p = 0.021). The
sequence motif variation towards tetra-proline conﬁgura-
tion was observed in 2 symptomatic individuals during time
of infection. The results also revealed the existence of a
negative selective pressure, as well as codons under positive
pressure in the sequences.
Conclusion: In this HIV-2-infected individuals studied, it
was observed a need for a greater degree of Nef protein con-
servation in a symptomatic phase. Sequences altered and
potentially critical for the Nef function in vivo, in earlier
stages of infection, may contribute at some level to a dif-









rediction of R5, X4 HIV-1 coreceptor usage based on
hysicochemical properties of envelope V3- loop using
rtiﬁcial neural network
. Falahi1, M. Ravanshad2,∗, A. Kenarkoohi1
Department of Virology, Faculty of Medical Sciences, Tar-
iat Modares University, Tehran, Iran, (Islamic Republic of)
Department of Virology, Faculty of Medical Sciences,
4115-331, Iran, (Islamic Republic of)
Background: HIV-1 cell entry commonly uses, in addition
o CD4, one of the chemokine receptors CCR5 or CXCR4 as
oreceptor. Human immunodeﬁciency virus type 1 (HIV-1)
solates can be classiﬁed phenotypically according to the
rimary coreceptor used to enter the cells. Third variable
egion (V3- loop) of the gp120 subunit of the HIV-1 enve-
ope protein has been identiﬁed as a major determinant of
oreceptor usage. Knowledge of coreceptor usage is crit-
cal for monitoring disease progression and for supporting
herapy with the novel drug class of coreceptor antagonists.
redictive methods for inferring coreceptor usage based on
he third V3- loop region can provide us with these monitor-
ng facilities while avoiding expensive phenotypic assays. In
his study we applied an artiﬁcially neural network on phys-
ochemical data, derived from V3- loop sequence to predict
oreceptor usage of viral isolate.
Methods: At ﬁrst authors has collected two reliable set of
ata that deﬁne the biochemical and structural conditions
f co receptor usage of virus. In the next step we have devel-
ped an ANN models to predict virus coreceptor usage and
ompare the results of ANN models with MLR model. In the
NN model, two levels of 1 and 2 are used as output vector
r goal, respectively for R4 and R5 and the physiochemical
spects are input variables, also it was in MLR model.
Results: The process of training and testing of this new
odel is done using a set of collected data. ANN model with
2 = 0.99 and RMSE = 15.18 in training stage and R2 = 0.91 and
MSE = 187.8 in testing stage is superior in predicting the
oreceptor usage. Several statistical and graphical criterions
re used to check the accuracy of the model.
Conclusion: The coreceptor usage values predicted by
he ANN model satisfactorily compared with the measured
ata. The predicted values were also compared with those
redicted using linear regression model. The presented
ethodology in this modeling is a new approach in estimat-
ng coreceptor usage and can be combinedwith othermodels




linical and immunologic response of HIV patients on dif-
erent ART regimens at Gondar University Hospital (GUH). Ergete
I-TECH ETHIOPIA, ADDIS ABABA, ET, Ethiopia
Background: As HIV treatment program expands in








































































































ased on WHO / National guideline criteria’s. Like ﬁrst line
RT combinations for initiating treatment and second line
RT combinations for treating ﬁrst line treatment failure
onditions. There are many combinations of ﬁrst line drugs
nd it is important to deﬁne are all these ﬁrst line regimens
qually effective in real clinical set ups.
Methods: We conducted a retrospective chart review
f the outcome of different ART regimens among 300
IV- infected patients whose CD4 count was less than
00 cells/mm3 on initiation of ART and has regular fol-
ow up at Gondar University Hospital in Gondar, Ethiopia
etween September 2008 and March 2009, who received
tandard ﬁrst line combination ART regimens. Group 1
N = 100) include those treated with AZT, 3TC, EFV/NVP
ombinations, Group 2 (N = 100) include those treated with
4T, 3TC, EFV/NVP combinations and Group 3 (N = 100)
nclude those treated with TDF, 3TC, EFV/NVP combina-
ions.
Results: There were no difference between Group 1,
and 3 with regard to: IRIS [Ten (10%), Thirteen (13%)
nd Eleven (11%), P = ns] respectively; new opportunistic
nfections [Four (4%), Seven (7%), and Three (3%), P = ns]
espectively; average CD4 increment by 30% [Eighty (80%),
eventy six (76%), and Eighty three (83%), P = ns] respec-
ively and death [Six (6%), Five (5%), and Four (4%), P = ns]
espectively. However, adverse drug side effect occurs more
requently in Group 1 and 2 than in Group 3 [Eighteen (18%)
nd Twenty (20%) versus Three (3%), P = 0.03] respectively,
hich more frequently resulted poor adherence in Group
and 2 than Group 3 [Seventeen (17%) and Sixteen (16%)
ersus Three (3%), P = 0.05] respectively.
Conclusion: This manuscript shows that in a retrospective
eview of HIV patients who are in different Antiretroviral
rug combination regimens attending follow ups at GUH,
he clinical and immunological responses for the different
RT regimens are similar and comparable however it depicts
ifferences in areas of drug side effects and adherence prob-
ems. Therefore different ﬁrst line ART drug combinations
election in resource poor countries can be guided by drugs
ide effect and adherence issues.
oi:10.1016/j.ijid.2010.02.2025
5.002
omparison of efavirenz and nevirapine based HAART reg-
mens in 4187 patients with up to 6 years of follow up, a
rospective, open label observational study
. Cortes1,∗, C. Beltran2, M. Wolff 1
University of Chile School of Medicine, Chilean AIDS
ohort, Santiago, Chile
University of Santiago, Chilean AIDS Cohort, Santiago,
hile
Background: Non nucleoside reverse transcriptase
nhibitors (NNRTI) based regimens are widely recommended
s 1st line HAART and they are preferred in resource
onstrained settings due to high efﬁcacy and low cost. Few
tudies compare effectiveness of efavirenz (EFV) and nevi-
apine (NVP) in large, prospective cohorts with extended
ollow up (f/u). Objective: To determine the effectiveness,
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f patients with EFV versus NVP based regimens as initial
AART in a nation wide cohort.
Methods: Prospective, open label, f/u of patients
nrolled in the Chilean AIDS Cohort (ChiAC) from October
001 to March 2008. All subjects receiving at least one dose
f EFV or NVP were included. Primary outcomes were sur-
ival, maintenance of initial HAART, reason for change of
NRTI, viral suppression and immune recovery.
Results: Of 5120 patients initiating ﬁrst HAART in ChiAC,
187 started a NNRTI based regimen (plus 2 NRTIs); 3107
74.2%) with EFV and 1080 (25.8%) with NVP. Median f/u
as 2.7 years. At baseline the NVP group had a signiﬁcantly
ess advanced stage (CDC classiﬁcation) and higher median
D4 count (151 vs 86 cell/mm3 in EFV, p < 0.001), but similar
iral load (VL) compared to the EFV group. Rate of change
r discontinuation was signiﬁcantly lower for EFV (12.8% vs
2.3%, p < 0.001), due to fewer adherence problems or toxi-
ity. Timing for change was similar in both arms (median 950
s 1008 days for EFV and NVP respectively). There were no
tatistical differences in viral suppression rate (<80 cps/mL)
t any time: 67.2, 74.9, 74.4, 65.1, 59.8% vs 63.6, 74.3,
2.7, 61.7, 59.4% at 6, 12, 24, 36 and 48 months for EFV
nd NVP respectively. At 12 months of f/u median CD4 cell
ount was similar for groups (242 for EFV and 250/mm3 for
VP). Mortality for the total period was 2.89 and 2.85 per
00pts-year for EFV and NVP respectively (p =NS).
Conclusion: Efavirenz based HAART regimens were asso-
iated with similar viral and immune outcomes as Nevirapine
ased regimens, despite more severe disease at baseline in
he EFV group. Discontinuation of NVP was more frequent,




he economic impact of introducing HIV/AIDS guide-
ine into Colombian National Drug Formulary. Cost-
ffectiveness analysis
.V. Lemos Luengas ∗, B.C. Castan˜eda, E. Quevedo, C.
astillo, L.R. Lemos
Fundacion para el Desarrollo y Apoyo en Salud Internacional
FUDASAI), Bogota, Colombia
Background: Colombia has >165000 people infected
ith human immunodeﬁciency virus (HIV). In 2009, the
orld Health Organization (WHO) estimated only 40% had
ntiretroviral therapy coverage. Colombia’s AIDS treatments
uidelines became available in 2006 and are currently being
sed by physicians in their daily practice. However, these
uidelines have not yet been evaluated with respect to their
elative costs and effectiveness.
Methods: A Markov model was developed using TreeAge
Pro-2009 and clinical experts. Success probabilities were
erived from published randomized controlled trials. Drug
osts were obtained from the 2009 Drug Price Guideline from
ogotá and the ISS 2008 Manual. Hospitalization costs were
btained from theWest Kennedy Hospital, Bogotá 2008/2009
atabase, adjusted to 2008. One-way and two-way sensitiv-
ty analyses were performed to test the model’s robustness
y varying clinical success rates and costs of antiretrovirals.
